<DOC>
	<DOCNO>NCT01337258</DOCNO>
	<brief_summary>The objective project conduct retrospective economic analysis use dutasteride prevention prostate cancer base data REDUCE clinical trial . REDUCE 4-year , phase 3 , randomize , double-blind , parallel assignment clinical trial use dutasteride compare chemopreventive treatment . The REDUCE trial four-year , international , multicenter , randomize , double-blind , placebo-controlled , parallel group study . There 790 investigator 42 country .</brief_summary>
	<brief_title>Economic Analyses REDUCE Trial</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Men age 50 75 year serum prostatespecific antigen ( PSA ) ≥2.5 ng per milliliter ≤10 ng per milliliter ( men age 5060 year ) ≥3.0 ng per milliliter ≤10 ng per milliliter ( men age &gt; 60 year ) single , negative prostate biopsy ( 612 core ) within 6 month prior enrollment ( independent study ) Principal exclusion criterion one prior prostate biopsy highgrade intraepithelial neoplasia ( HGPIN ) atypical small acinar proliferation ( ASAP ) preentry prostate biopsy prostate volume &gt; 80 ml , previous prostate surgery International Prostate Symptom Score ( IPSS ) ≥25 ≥20 already alphablocker therapy BPH</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>cost effectiveness</keyword>
	<keyword>dutasteride</keyword>
	<keyword>elevate risk population</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>prevention</keyword>
</DOC>